Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179019 · ClinicalTrials.gov registry record · Phase 2
Calcium Channel Blockade in Primary Aldosteronism
A Phase 2 study of Primary Aldosteronism and Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral), sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04179019 is a Phase 2 study of Primary Aldosteronism and Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 15 participants, below the 3,268-participant average among 4 other Primary Aldosteronism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04179019, a Phase 2 study of Primary Aldosteronism and Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral), has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.
Conditions Studied
Interventions
- DRUG Amlodipine
Study Locations (1)
Massachusetts
- Anand Vaidya - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04179019
The ClinicalTrials.gov registry entry for NCT04179019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,268-participant average among 4 other Primary Aldosteronism trials with a reported enrollment target (100% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Aldosteronism appearing as the primary indexed condition, and to 1 intervention - of which Amlodipine is the first listed.
NCT04179019 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04179019 about?
NCT04179019 is a clinical study titled "Calcium Channel Blockade in Primary Aldosteronism". This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.
What is the current status of trial NCT04179019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-09-01. Estimated completion is 2023-12-30.
What conditions does trial NCT04179019 study?
This clinical trial studies the following conditions: Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral).
What interventions are being tested in trial NCT04179019?
The interventions under investigation include: Amlodipine (DRUG).
Who is sponsoring clinical trial NCT04179019?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04179019 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Aldosteronism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CIN-107 in Adults With Primary Aldosteronism
COMPLETED · Phase 2
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
ACTIVE NOT RECRUITING · NA
-
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
COMPLETED
Explore more on PlainTrial
Primary Aldosteronism
All registered trials for this condition
Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.